Skip to content
OpenCapital
Get started

Axsome Therapeutics AXSM Net interest and investment income (loss)

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$12.89B+52.0%
Enterprise value$12.81B+52.9%
P/S18.2×-1.4×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity4×+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's net interest and investment income (loss).

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axsome Therapeutics's net interest and investment income (loss)?
Axsome Therapeutics (AXSM) reported net interest and investment income (loss) of -$1.19M in Q1 2026.
How has Axsome Therapeutics's net interest and investment income (loss) changed year-over-year?
Axsome Therapeutics's net interest and investment income (loss) increased by 51.3% year-over-year, from -$2.43M to -$1.19M.
What is the long-term trend for Axsome Therapeutics's net interest and investment income (loss)?
Over 4 years (2021 to 2025), Axsome Therapeutics's net interest and investment income (loss) has grown at a 3.6% compound annual growth rate (CAGR), from -$5.7M to -$6.56M.